J. Goldman & CO LP Sage Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.27 Billion
- Q2 2024
A detailed history of J. Goldman & CO LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 116,842 shares of SAGE stock, worth $842,430. This represents 0.04% of its overall portfolio holdings.
Number of Shares
116,842Holding current value
$842,430% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding SAGE
# of Institutions
217Shares Held
48.2MCall Options Held
854KPut Options Held
195K-
Vanguard Group Inc Valley Forge, PA6.42MShares$46.3 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$39.5 Million0.99% of portfolio
-
Black Rock Inc. New York, NY5.22MShares$37.6 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$32.2 Million0.81% of portfolio
-
State Street Corp Boston, MA2.47MShares$17.8 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $428M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...